We took an effective chemotherapy drug and
made it much safer, with no side effects.
Conventional chemotherapy damages normal cells as well as cancer cells, causing toxicities that limit treatment. ONX-1006 carries paclitaxel (PTX), a widely used chemotherapy drug, chemically bound in stable nanoparticles designed to concentrate PTX in tumors while protecting normal cells.
ONX-1006 is being prepared for a Phase I/IIa clinical trial in patients with Stage IV pancreatic cancer.
1. Outstanding Results and Development Goals
-
Continuous Treatment:
One year or longer
of continuous ONX-1006 (PTX)
chemotherapy treatment.
-
Without Side Effects:
Continuous chemotherapy treatment
without side effects,
enabling ongoing tumor cell death.
-
Outstanding Antitumor Efficacy:
20% greater tumor reduction
than Abraxane at the same weekly PTX dose
in a pancreatic cancer animal test.
-
Tumor Elimination Goal:
90–100%.
-
One-Year Survival Goal:
70%.
Continuous treatment without side effects
is intended to enable ongoing tumor cell death
and ultimately tumor elimination.
Treatment duration, tumor elimination,
and survival figures are future clinical
development goals based on preclinical results.
2. Supporting Safety Data
-
Over 30 preclinical tests
and 4,000 pages
of supporting data.
-
Excellent safety findings in rat
and beagle dog GLP toxicity studies.
-
Beagle dogs, weekly for 4 weeks:
No Side Effects
at
480 mg PTX equivalent
(60 kg adult).
-
Beagle dogs, weekly for 13 weeks:
No Side Effects
at
320 mg PTX equivalent
(60 kg adult).
-
2.4× and 1.6×
a typical 200 mg Abraxane (PTX) dose.
Abraxane’s label reports severe side effects.
3. FDA IND Package and SEND Completion
On November 6, 2026, Onselex announced completion
of the FDA IND application package for ONX-1006.
-
FDA IND Application Package:
Complete nonclinical summaries,
Investigator's Brochure, and Phase I/IIa
clinical trial protocol for Stage IV
pancreatic cancer.
-
15 SEND-applicable studies and 199 electronic datasets:
All passed Pinnacle 21 validation, a tool used by the FDA.
-
25 complete nonclinical study reports
totaling
2,122 pages.
-
Remaining Major Step:
cGMP clinical manufacturing batch.
Onselex is raising capital to fund
this batch and the first human trial.
The IND has not yet been submitted.
FDA submission will follow completion
of the cGMP clinical batch.
4. Pancreatic Cancer Market Opportunity
RASONQUE – Revolution Medicines (RVMD)
-
FDA Approval:
Aug. 2026, metastatic pancreatic cancer
in eligible adults.
-
Market Capitalization:
About $45 billion for Revolution Medicines
(early Oct. 2026).
-
Survival Benefit:
~6.5 months longer.
-
One-Year Survival Rate:
53.2%.
-
Grade ≥3 Treatment-Related Adverse Events:
43.6%.
Despite advances in pancreatic cancer treatment,
severe toxicities and limited long-term survival
remain major challenges. We believe ONX-1006
can address both challenges.
5. Our Goals
-
Development Roadmap:
cGMP clinical manufacturing →
U.S. FDA IND filing →
South Korea MFDS clinical trial approval →
First clinical trial in South Korea (Cohort 1).
-
First Cohort:
Phase I/IIa clinical trial planned for eight treatment-naïve patients with Stage IV pancreatic cancer.
-
U.S. FDA IND Integration:
Plan to include the South Korean clinical trial in the U.S. FDA IND and
submit the clinical results to the FDA.
-
Protect patients' quality of life.
-
Extend and save millions of lives.
We invite investors and strategic partners
to join Onselex in transforming cancer
treatment and bringing a new generation
of therapies to patients worldwide.
For investment or partnership opportunities,
please visit our
Investment & Partner Inquiry page
and complete the inquiry form.
We look forward to welcoming you as part
of Onselex’s journey.
Ernie Shin